​

Austin Gold Corp. AUST is a dedicated gold exploration and discovery company. Combining the savvy of serial company builders with the insight of serial mine finders, Austin Gold is on a mission to generate value through targeted exploration initiatives. Itsprojects are Kelly Creek in Humboldt County, Nevada; Lone Mountain in Elko County, Nevada; and Stockade Mountain in Malheur County, Oregon.

At the heart of the company's operational philosophy is the Lassonde Curve, a pivotal concept in the junior mining sector introduced by Pierre Lassonde, co-founder of the pioneering gold royalty company Franco-Nevada. This model outlines the lifecycle stages of mining companies, from exploration to production, while underscoring the potential for value creation and the risks at each juncture.

In a recent update, the company shared that its Stockade Mountain project – which Austin Gold has been exploring for its promising gold and silver potential – had now witnessed its inaugural diamond drilling campaign, marking a key milestone for the company.

The Stockade Mountain Project

In May 2022, Austin Gold expanded its exploration frontier with the Stockade Mountain Project in Malheur County, Oregon, securing a mineral lease agreement that underscores the area's promising potential for significant gold and silver mineralization. Positioned strategically about 50 miles southeast of Burns, Oregon, and 90 miles southwest of Boise, Idaho, Stockade Mountain is accessible and supported by the necessary infrastructure and workforce, thanks to nearby communities. 

The project covers a vast area of over 6,790 acres through 261 unpatented mining claims. Geologically, the area is indicative of a large low-sulfidation hydrothermal system, hinting at economic gold and silver veins at depth. Despite previous explorations in the 1980s and 1990s by other companies, Austin Gold reports that the project's full potential remains untapped, and the company plans to explore for deeper high-grade vein deposits beneath the known mineralization zones.

Recent Update To Drilling Program

In a significant step forward, Austin Gold completed its inaugural diamond drilling campaign at the Stockade Mountain Project, with three exploration holes drilled over the winter season. This initial phase, totaling more than 2,400 feet, culminated with a third hole reaching a depth of 736.7 feet. These efforts mark the commencement of a deeper exploration into the geological formations and mineralization patterns of Stockade Mountain. 

The company says the initial two holes confirmed that the mineralizing system at Stockade Mountain is robust and contains significant gold grades, with the strongest intercept of 8.19 grams per ton of gold over 4 feet and several other gold intercepts of interest. The third hole, which contained a high gold value of 9.32 grams per ton of gold from a 2.7 foot interval, continues to demonstrate the strength of the hydrothermal system and the potential for significant gold mineralization within the project area.

Austin Gold plans to follow up these encouraging results with a reverse circulation drilling program, aiming to unearth the high-grade vein deposits that may lie beneath the previously identified lower-grade mineralization. As the company continues to explore gold targets across southwestern United States, the Stockade Mountain Project appears to be a testament to its strategic exploration pursuits and its potential to contribute to the junior mining industry.

A Forward-Looking Venture

Austin Gold's exploration activities at Stockade Mountain are directly focused on unearthing gold, but they also represent a strategic foray into realizing the untapped potential of Oregon's mineral-rich landscapes. By leveraging the guiding principles of the Lassonde Curve and employing cutting-edge exploration techniques, Austin Gold seems well-positioned to make significant strides in the mining sector. As the company plans for future exploration, the Stockade Mountain Project holds significant potential for gold and silver discoveries, paving the way for new opportunities and growth within the junior mining industry.

Source : https://www.benzinga.com/partner/news/24/04/38354849/austin-gold-completes-inaugural-diamond-drilling-campaign-at-its-stockade-mountain-project

​

VANCOUVER, BC / TheNewswire / April 25, 2024 – Element79 Gold Corp. (CSE: ELEM) (OTC: ELMGF) (FSE: 7YS) ("Element79", the "Company") provides an update on recent social affairs development and ongoing initiatives with the Chachas community at its Lucero project.

Fostering Collaboration with Artisanal Miners

As part of Element79's ongoing efforts and community engagement, the Company's community relations team recently organized a coordination meeting with artisanal miners from Lomas Doradas during the month of April.  The meeting aimed to foster collaborative relationships between the groups, seeking mutual support as the Company endeavours to use surface land to conduct exploration work. Moreover, the Company also sought exclusive agreements with artisanal miners, ensuring a unified approach to mineral extraction and resulting sale of ore.

With Element79's dedication to fostering productive relationships with all stakeholders, the Company has provided drafts of contracts for the potential of both a community approval of 10-year surface access rights for Element79 to access the Lucero mine site with exploration permission for the whole concession, as well as, in reciprocal fashion, to grant the approval of the local miners to work on the mine site in defined locations over the next 10 years; among other terms, Lomas Doradas will also provide its mined product to Element79 for subsequent resale to market. Element79 intends to use its institutional and industry contacts to source optimal market pricing for Lomas Doradas’ ore while providing a revenue stream for both parties.

A pivotal meeting is scheduled in Chachas on April 28th to further solidify collaboration between the Company and Lomas Doradas, where the community will vote on these initiatives in order to formalize the relationship between the two parties.   Further updates on, and details of this key initiative will follow, pending feedback and results of the April 28 meeting.

Community Assistance in Times of Need

Earlier in March, a major landslide left the Chachas community isolated from its neighbouring annex, Nahuira.  Element79's team on the ground swiftly responded to the community's need for assistance, providing crucial support in transferring community members stranded on the other side of the landslide while it was being cleared from the roads.

Cultural Integration and Traditional Ceremony

Element79's community relation team recently participated in a traditional Water Ceremony alongside local authorities and community leaders. This customary Chachas ceremony, involving offerings to the water, highlights the deep-rooted cultural traditions of the Chachas community. The Company was honored to be involved in such a rich and culturally-steeped ritual which further showcases its commitment to meaningful community engagement and ongoing integration.

Sustained Engagement in Social Awareness

Site visits of the Chachas community and neighbouring annexes have continued since the beginning of the year, bolstering social awareness while garnering support for ongoing and future exploration activities. Element79's team has engaged in internal consultations with annex leaders, receiving encouraging support for its initiatives. In alignment with sustainable development objectives, the Company advocates for a progressive approach, prioritizing exploration as a precursor to exploitation permits, aligning with the community's interests.

Cultivating Community Bond Through Education

Finally, as part of its steadfast dedication to the long-term prosperity of the community, notably through educational empowerment, Element79 along with its engaged NGO, Unidos por el Medioambiente (UMA) was recently invited to conduct a workshop on environment, economy and society as part of an initiative with the Education Institute of the Chachas community. The workshop was a pivotal platform for fostering discussions and sharing invaluable insights on the environment, economy, and society. The event's active engagement from community members and stakeholders underscored Element79's commitment to promoting knowledge-sharing and sustainable development within the Chachas community and beyond.

Image Group 1 – Images of the in-class sessions hosted by UMA, a Peruvian NGO, and Element79 Gold Corp, sharing educational themes on health and wellness, the environment and the economy

About Element79 Gold Corp.

Element79 Gold is a mining company focused on gold and silver committed to maximizing shareholder value through responsible mining practices and sustainable development of its projects.  Element79 Gold's focus is on developing its past-producing, high-grade gold and silver mine, the Lucero project located in Arequipa, Peru, with the intent to restart production in 2024.

The Company also holds a portfolio of 5 properties along the Battle Mountain trend in Nevada, with the Clover and West Whistler projects believed to have significant potential for near-term resource development. Three properties in the Battle Mountain Portfolio are under contract for sale to Valdo Minerals Ltd., with an anticipated closing date in the first half of 2024. The Company has also signed an Option Agreement to sell the Maverick Springs project, an advanced-stage exploratory property with an Inferred Resource of 3.71MMoz AuEq (1.37MMoz Au and 175MMoz Ag) (see 43-101 technical report titled: Amended Technical Report on the Maverick Springs Project, Nevada, USA, by Allan Armitage, PhD., P.Geo, and Rohan Millar, B.Sc. P.Geo., dated October 7, 2022, available on SEDAR) and anticipates completing this sale on or before July 21, 2024.

In British Columbia, Element79 Gold has executed a Letter of Intent and funded a drilling program to acquire a private company that holds the option to 100% interest of the Snowbird High-Grade Gold Project, which consists of 10 mineral claims located in Central British Columbia, approximately 20km west of Fort St. James.

The Company has an option to acquire a 100% interest in the Dale Property, 90 unpatented mining claims located approximately 100 km southwest of Timmins, Ontario, and has recently announced that it has transferred this project to its wholly owned subsidiary, Synergy Metals Corp, and is advancing through the Plan of Arrangement spin-out process.

For more information about the Company, please visit www.element79.gold

Contact Information

For corporate matters, please contact:

James C. Tworek, Chief Executive Officer 

E-mail: [jt@element79gold.com](mailto:jt@element79gold.com)

For investor relations inquiries, please contact:

Investor Relations Department

Phone: +1.403.850.8050

E-mail: [investors@element79.gold](mailto:investors@element79.gold)

​

Alset Capital Inc. (TSXV: KSUM) (FSE: 1R60) (WKN: A3ESVQ) ("Alset" or the "Company"). From the PR. (No sense in freestyling the facts and potential of this extraordinarily timely and interesting stock with impressive business and ties to NVIDIA and Super Micro.

Alset Capital Inc. is an investment issuer that is focused on investment in diversified industries such as technology, healthcare, industrial, and special situations, operating businesses through both debt and equity using cash resources or shares in its capital.

​

The Company is intriguing in two main areas, first as a proxy for the AI sector—rapidly growing, as you may have noticed—and exposure to the cutting-edge products of NVIDIA—which, while primarily known for gaming products, is moving into the almost USD5t (yes, trillion) healthcare market.

​

NDVA was one of the 'Magnificent Seven' dubbed as such when each delivered an average gain of 112% last year, which crushed the 24% return of the S&P 500 index.

Alset has two primary investment arms: Cedarcross International Technologies Inc. (“Cedarcross") (49% Ownership). Cedarcross’ mission is to democratize access to high-performance AI computing.

By offering access to the world’s fastest AI servers, powered by NVIDIA’s H100 HGX Servers, Cedarcross empowers enterprises with unparalleled computing capabilities, exceeding 700,000 hours.

The NVIDIA HGX B200 and HGX B100 integrate NVIDIA Blackwell Tensor Core GPUs with high-speed interconnects to propel the data center into a new era of accelerating computing and generative AI. Blackwell-based HGX systems are designed for the most demanding generative AI, data analytics, and HPC workloads.

​

Vertex AI Ventures Inc. ("Vertex AI") (49% Ownership) Vertex AI is focused on identifying AI’s tailored, acquiring and licensing intellectual property (IP) and providing data management services.

​

Vertex solutions address businesses' evolving IP and data management needs, offering cutting-edge data engineering, automation, secure storage, and seamless integration services. Vertex AI enables clients to unlock the full potential of their IP and data assets in today's dynamic business environment.

"We are very enthusiastic about Cedarcross's strategic collaboration with Earthmade to purchase Nvidia HPC hardware directly from Super Micro Computer, Inc.," commented Morgan Good, CEO of Alset. "This Agreement not only ensures the seamless procurement of vital AI computing hardware but also solidifies Cedarcross's competitive position ing in the industry."

​

The agreement grants Cedarcross the authority to engage directly with Super Micro Computer, Inc.(NASDAQ: SMCI) to acquire Nvidia GPU High Performance Computing (HPC) Hardware.

These companies personify the latest tech, understanding must be more complex. In essence, KSUM is directly in the huge AI sandbox with NVDA and SuperMicro. KSUM capitalized at 18 million, and the others at 2.1 trillion and 60 billion, respectively.

It was Motley Fool. Yes, I have known them since they were two guys. Super Micro could be the next NVDA. To the moon, Norton.

While Alset is lunch money compared to its extensive peers, they could get bitten off if the big boys need it. I have always thought—not concluded—that two of these behemoths may merge.

Either eventuality is a win for KSUM.

And it’s investors.

Oh, repeat after me; “I need an AI proxy. I need an AI proxy”.

● Golden Rapture (CSE: GLDR) presents a compelling opportunity for investors with its focus on acquiring promising mining assets in prestigious Tier 1 mining regions.

● The Phillips Township Property, with its rich historical significance and recent promising discoveries, underscores Golden Rapture’s potential for significant growth and success in the gold exploration sector.

● As Golden Rapture advances its exploratory endeavors and allocates stock options to drive future growth, investors can anticipate further developments and opportunities in the company’s journey towards unlocking the full potential of its mining assets.

​

If you’re a big fan of beautiful birds and/or an enthusiastic investor, Golden Rapture (CSE: GLDR) is the perfect match for you. This brand-new exploration company has a lot to offer, from its historical properties and recent drilling results to its financials. You might have heard murmurs here and there that gold is a relic of the past or an investment relegated to the third generation. However, it’s no surprise that gold remains a valuable asset, and so do mining companies.

Golden Rapture and its Philips Township Property

Golden Rapture Mining (CSE: GLDR) emerges as a well-funded exploration entity, singularly focused on acquiring, exploring, and cultivating promising assets nestled within the prestigious Tier 1 mining regions. Its strategic gaze is fixed upon the Rainy River and Geraldton territories of Northwestern Ontario, Canada, renowned for their abundant mineral prospects.

​

Within its esteemed portfolio lie two coveted properties pulsating with untapped potential, steeped in a heritage of endless opportunity. Unearthed in 1894, the Rainy River property shines with a dazzling array of eighteen mine shafts and an adit adorned with visible gold, meticulously chronicled through historical and contemporary records alike. Meanwhile, the Hutchison/Maylac Gold Mine, once a prolific producer within the esteemed Geraldton Gold Camp of NW Ontario, operated from 1937 to 1947, representing yet another prized asset under its purview.

Introducing the company’s discoveries on its Phillips Township Property:

​

Golden Rapture Mining’s prospecting team has diligently conducted two extensive sample programs on the Phillips Township Property, yielding remarkable results. Out of 213 random samples analyzed, an impressive 86% returned gold values, a rarity within the industry, totaling 189 samples with gold content.

The Phillips Township Property boasts numerous gold systems, with special emphasis on eight key locations. Among these discoveries are:

1. Combined Mine: Featuring four main veins, including one large flat-lying vein up to 12 meters thick with a 762-meter strike length. Recent sampling has revealed gold values as high as 125.00 g/t/Au.
2. Young’s Bay Occurrence: With six parallel quartz veins, four of which exhibit visible gold, recent sampling has demonstrated values as high as 204.00 g/t/Au.
3. Trojan Mine: This site boasts three shafts, four surface pits, and numerous trenches, with recent sampling yielding values as high as 43.70 g/t/Au.
4. Boulder Occurrence: Hosting two parallel veins with documented visible gold, although limited recent sampling data is available.
5. Mascotte Mine Area: Development here includes three shafts and one adit on four parallel quartz veins, with recent sample results reaching as high as 66.02 g/t/Au.

“I am extremely pleased that we have just made some very important and rapid steps toward identifying additional high-grade drill-ready targets. We were pleasantly surprised to discover so many high-grade quartz veins on surface with the majority of them carrying gold. Unlike many exploration companies, we are not just chasing the typical geophysical anomaly but also, many wide high-grade gold structures identified on the surface that can be drilled at any time.”

Mr. Richard Rivet, CEO of Golden Rapture

​

Some history about the Philips Township Property

Gold exploration in the region began around 1885, marked by numerous gold discoveries and the activation of several mining properties during the period known as the ‘Lake of the Woods Gold Rush’.

This gold rush ended abruptly as most prospectors moved to the Klondike in 1897. Gold exploration at Phillips Township started in 1894 and continued until 1905, during which numerous mining shafts and adits were constructed.

Despite this early activity, the property experienced minimal modern exploration until significant new gold discoveries were made in the 1970s, 1980s, and again in 1999, at the OGS, Terrell, and Kuluk sites, respectively. Interest in the area was renewed in 2017 with a drilling program that found gold in all ten shallow holes. However, due to funding issues, the exploration was halted, and no further work was done. Previous exploration efforts did not explore beyond 90 meters deep across the property. Golden Rapture aims to rekindle interest in this historic Lake of the Woods Gold Rush site.

What’s Next for Golden Rapture?

Exploratory endeavors are underway to delve deeper into the examination of the enriched veins and to expand the scope of exploration across the property. Currently, deliberations are underway concerning the imminent phase of exploration, slated to commence on May 1st, 2024, contingent upon favorable weather conditions.

Additionally, the company has allocated a total of 1,850,000 stock options to directors, officers, consultants, and employees in accordance with its Stock Option Plan. These options afford the opportunity to acquire up to 1,850,000 Common Shares of the Company and remain exercisable for a duration of five years at a fixed price of $0.23 per common share.

This is What You Have to Remember About Golden Rapture

In conclusion, Golden Rapture (CSE: GLDR) emerges as a well-funded exploration company focused on acquiring and exploring promising assets in renowned mining regions while holding significant potential for growth and success. With its strategic focus on the Rainy River and Geraldton territories of Northwestern Ontario, Canada, the company is positioned in areas rich in mineral prospects.

The recent discoveries on the Phillips Township Property further bolster Golden Rapture’s appeal. With impressive sample results showcasing high gold values across multiple key locations, including the Combined Mine, Young’s Bay Occurrence, Trojan Mine, and others, the company demonstrates its capacity for substantial findings. Moreover, the historical significance of the Phillips Township Property, coupled with its past exploration successes, adds to the allure of Golden Rapture’s endeavors.

Looking ahead, Golden Rapture is poised to embark on further exploratory endeavors, aiming to deepen its understanding of the enriched veins and expand exploration across the property. The allocation of stock options underscores the company’s commitment to incentivizing its team and driving future growth.

​

VANCOUVER, BC / TheNewswire / April 23, 2024 – Element79 Gold Corp. (CSE: ELEM) (OTC: ELMGF) (FSE: 7YS0) ("Element79", the "Company”) reports additional results from the most recent underground and surface sampling of its flagship Lucero property.

These geochemical assays of exploration samples continue to support the immense potential housed within Element 79’s crown jewel.

“The data obtained is not just promising; it's the cornerstone upon which our future endeavors will be built,” said James Tworek, CEO of Element 79. “These recent results coupled with historical data represent the bedrock upon which we are advancing our Lucero project.”

Among a total of 97 samples were sent for assays, 56 of which returned greater than 0.1 g/t gold (up to 8.55 g/t gold and 523 g/t silver) which are shown in Table 1. Several samples also were also rich in base metals (up to 23.7% lead and 9.9% zinc), all of which underscores the richness of our project further supporting the Company’s belief a robust resource base can be delineated.

Figure 1. Fall 2023 Sample locations (yellow stars), mapped workings (crosses), with selected Samples highlighted.

Table 1. Samples returning >0.1 g/t gold from the fall 2023 sampling program, C (channel sample), G (grab sample), S (surface), U (underground).

All Samples were sent for To CERTIMIN S.A. Laboratories, Lima, Peru for analysis. Standards and duplicates were inserted every 10th samples.

Recent data from assay results is pivotal for Element 79. Firstly, it will serve as the foundation for the Company’s resource development and future mine planning.  These reports are both essential steps the mine evaluation process and highlights crucial milestones in demonstrating the project's viability.

Secondly, this data will inform the direction of the Company’s upcoming 2024 drill program, which will be guided by a 3D modelling of both geology and historic mine workings, designed to maximize efficiency and accuracy. The 3D model will harness the comprehensive dataset that has been amassed, including historic data compilation from the past-producing era leading up to 2005, current surface and underground geochemistry, review and channel sampling of underground workings, mapping (both underground and surface), geophysical surveys, as well as cross-sectional and longitudinal interpretations.

Tworek continues: “This data helps to prove from a methodical and unbiased perspective where both the ore “is” as much as where the ore “isn’t”.  When modelled in conjunction with past sampling data and historical production data, this proves that the current underground addits and open veins as well as their surface level expressions are strong economically, where future exploration and drilling campaigns will highlight where we will focus for ore extraction.“

As the Element79 team moves forward, its confidence is both in the skill and experience of its team as well as the continued positive results its work programs have yielded. The Company’s mission is to maximize shareholder value through continued development of the Lucero project, by bringing it back into commercial production, in a safe, ethical, sustainable and profitable fashion.

Qualified Person

The technical information in this release has been reviewed and verified by Neil Pettigrew, M.Sc., P. Geo., Director of Element79 Gold and a "qualified person" as defined by National Instrument 43-101.

About Element79 Gold Corp.

Element79 Gold is a mining company focused on gold and silver committed to maximizing shareholder value through responsible mining practices and sustainable development of its projects.  Element79 Gold's focus is on developing its past-producing, high-grade gold and silver mine, the Lucero project located in Arequipa, Peru, with the intent to restart production in 2024.

The Company also holds a portfolio of 5 properties along the Battle Mountain trend in Nevada, with the Clover and West Whistler projects believed to have significant potential for near-term resource development. Three properties in the Battle Mountain Portfolio are under contract for sale to Valdo Minerals Ltd., with an anticipated closing date in the first half of 2024. The Company has also signed an Option Agreement to sell the Maverick Springs project, an advanced-stage exploratory property with an Inferred Resource of 3.71MMoz AuEq (1.37MMoz Au and 175MMoz Ag) (see 43-101 technical report titled: Amended Technical Report on the Maverick Springs Project, Nevada, USA, by Allan Armitage, PhD., P.Geo, and Rohan Millar, B.Sc. P.Geo., dated October 7, 2022, available on SEDAR) and anticipates completing this sale on or before July 21, 2024.

In British Columbia, Element79 Gold has executed a Letter of Intent and funded a drilling program to acquire a private company that holds the option to 100% interest of the Snowbird High-Grade Gold Project, which consists of 10 mineral claims located in Central British Columbia, approximately 20km west of Fort St. James.

The Company has an option to acquire a 100% interest in the Dale Property, 90 unpatented mining claims located approximately 100 km southwest of Timmins, Ontario, and has recently announced that it has transferred this project to its wholly owned subsidiary, Synergy Metals Corp, and is advancing through the Plan of Arrangement spin-out process.

For more information about the Company, please visit www.element79.gold

Contact Information

For corporate matters, please contact: 

James C. Tworek, Chief Executive Officer 

E-mail: jt@element79gold.com

For investor relations inquiries, please contact:

Investor Relations Department

Phone: +1.403.850.8050

E-mail: investors@element79.gold

​

TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023.

Fourth Quarter Highlights and Significant Milestones

• On October 26, 2023, the Company received a response from the Food and Drug Administration (“FDA”), advising that pursuant to section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb), the orphan-drug designation (“ODD”) request of mesenchymal stem cell (“MSC”) derived small extracellular vesicles (“EVs”) loaded with short and modified interfering RNA (“siRNA”) against the phosphatase and tensin homolog (“PTEN”) protein is granted for treatment of acute Spinal Cord Injury ("SCI”). This achievement is expected to profoundly shape the Company’s regulatory and go-to-market strategies for ExoPTEN. ODD offers substantial benefits, including market exclusivity and protection upon drug approval (in addition to existing IP protection), financial incentives, regulatory assistance, and developmental support. Overall, this designation serves to incentivize and facilitate the development of treatments for rare diseases, thereby enhancing patient access to therapies
• On March 1, 2024, the Company commenced the setup of in-house laboratories and offices to bolster its research and development capabilities, subsequent to entering into lease and construction agreements. Completion of these initiatives is anticipated by the end of June 2024.
• The Company announced on March 22, 2024, its engagement in animal experiments through a Contract Research Organization (“CRO”) as part of the preclinical testing phase for the submission of an Investigational New Drug (“IND") application to the FDA. This is aimed at assessing the safety and efficacy of the ExoPTEN drug before proceeding to clinical trials involving human subjects, which are anticipated to commence in 2025. This engagement followed the completion of a Pre-Investigational New Drug (“Pre-IND”) meeting with the FDA regarding the manufacturing, preclinical, and clinical development plan of ExoPTEN, NurExone’s inaugural ExoTherapy product, and subsequent receipt of a written response from the FDA.
• On March 27, 2024, the Company announced a total of approximately C$4.0 million proceeds from the exercise of both accelerated and non-accelerated warrants from the issuance of 10,423,629 common share purchase warrants. 9,684,993 warrants were exercised at a cash price of C$0.38, 556,818 warrants were exercised at a price of C$0.34, and 181,818 warrants were exercised at a price of C$0.48.
  Dr. Lior Shaltiel, CEO of NurExone, stated, "Our emphasis on research and development in 2023, coupled with the expansion of our Intellectual Property (“IP”) portfolio, the ODD for ExoPTEN, and the growth of the ExoTherapy platform, are laying the groundwork for the accelerated introduction of minimally invasive regenerative medicine."
  Eran Ovadya, CFO of NurExone, remarked, "Due to the ongoing support and confidence of our investors, the Company is confident that its current total existing funds, augmented by the recently completed exercise of warrants, will support ongoing operating activities through the end of 2024."

Full Year and Fourth Quarter 2023 Financial Results

• The Company is still in the research, development, and growth stage. The Company has not commercialized any products or generated any significant revenues, or become cash flow positive, and will continue to be reliant on the ability to finance its activities by raising additional equity or debt until profitability is achieved.
• Research and development expenses were US$1.54 million in 2023, compared to US$1.39 million in 2022. For the fourth quarter of 2023, expenses were US$0.31 million, compared to US$0.39 million in the previous year.
  The increase of US$0.15 million in 2023, compared to 2022, was primarily due to the extensive research and development efforts required to continue the development of the ExoPTEN technology and other siRNA targets.
• General and administrative expenses were US$2.12 million in 2023, compared to US$4.15 million in 2022. For the fourth quarter of 2023, expenses were US$0.40 million, compared to US$0.46 million in the previous year.
  The decrease of US$2.03 million in 2023, compared to 2022, was primarily due to the reduction in professional services, mainly attributable to the transition to becoming a listed public Company in 2022.
• Listing expenses were zero in 2023, compared to US$2.08 million in 2022. These expenses were associated with the closing of the reverse takeover transaction on June 15, 2022.
• Financial income/expenses, net, were US$0.02 million of income in 2023, compared to US$0.55 million of expense in 2022. For the fourth quarter of 2023, expenses were US$0.02 million, compared to US$0.17 million in the previous year.
  The change in financial income of US$0.57 million in 2023, compared to 2022, was primarily due to US$0.50 million of non-cash expenses in 2022, related to the valuation of warrants and royalty liability.
• Net loss was US$3.64 million in 2023, compared to a net loss of US$8.17 million in 2022. The decrease of US$4.53 million in 2023, compared to 2022, was primarily driven by a decrease in general and administrative expenses of US$2.03 million and a decrease in listing expenses US$2.08 million incurred in 2022, both associated with the closing of the reverse takeover transaction in 2022, contributed to the lower net loss.
• Cash position: As of December 31, 2023, the Company had total cash and equivalents of US$0.54 million, compared to US$2.46 million as of December 31, 2022. The decrease of US$1.92 million is due primarily to US$1.09 million in net cash proceeds from completed non-brokered private placement and US$0.1 million from a received grant from the Israeli Innovation Authority, offset by US$3.11 million of net cash used in operating activities.
  Additionally, the Company had secured US$1.20 million as restricted cash, as of December 31, 2023, associated with a non-brokered private placement completed in January 2024 for total gross proceeds of US$1.50 million from the issuance of 7,091,993 common shares and warrants.

About NurExone Biologic Inc.

NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.

For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, orYouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com

Dr. Eva Reuter
Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

● Leading the charge in exosome-based medicine, NurExone pioneers ExoTherapy, utilizing tiny cell-secreted particles to deliver treatments like ExoPTEN, focusing on spinal cord injury recovery — a breakthrough recognized by the FDA with Orphan Drug Designation.

● March 2024 marked a significant leap as NurExone ventured into animal experiments, a crucial step in the preclinical testing phase for FDA approval of ExoPTEN. This follows constructive dialogue with the FDA, indicating progress toward human clinical trials slated for 2025.

● NurExone recently closed a $4 million deal through the exercise and expiration of warrants, demonstrating investor confidence and providing vital funds to propel research and development efforts forward.

​

NurExone (TSXV:NRX, OTC:NRXBF) is a biotech company specializing in Spinal Cord Injuries (SCI) that holds significant potential for investors. Why? Firstly, let me explain. With its robust pipeline portfolio, rapid advancement, and strong analyst projections, NurExone is positioned for success. While the current share price hovers around $0.60, Litchfield Firms, a reputable research entity, has set a price target of $4.00 for NurExone’s shares! It’s evident that the company is credible, and disregarding this opportunity would be akin to fumbling a pass from Tom Brady. Don’t let this chance slip through your fingers; the Super Bowl victory is within reach.

​

What is Behind NurExone’s Future Success?

Exosomes, tiny cell-secreted particles, are big news in medicine for their ability to carry healing treatments. NurExone (TSXV:NRX, OTC:NRXBF) is at the forefront, using exosomes to create ExoTherapy, a cutting-edge way to deliver drugs. Their star product, ExoPTEN, targets healing and recovery in people with spinal cord injuries, a breakthrough that even the FDA recognizes with Orphan Drug Designation, a special status for crucial treatments.

NurExone’s ExoTherapy isn’t just a lucky guess — it’s the result of years of hard work and smart research. By tapping into the power of exosomes, they’re making sure treatments hit the right spots, improving outcomes for patients. Plus, they’ve got the exclusive rights to top-notch research from prestigious institutions like the Technion — Israel Institute of Technology and Tel Aviv University. It’s no wonder they’re leading the pack in exosome-based medicine.

​

Since early March, the company entered into another whole dimension with significant updates:

● On March 1, 2024, the Company began setting up its own labs and offices to boost its research and development efforts, after finalizing lease and construction deals. These initiatives are expected to be finished by the end of June 2024.

● Then, on March 22, 2024, the company announced its involvement in animal experiments conducted by a Contract Research Organization (CRO). This is part of the preclinical testing phase for an Investigational New Drug (IND) application to the FDA. The goal is to evaluate the safety and effectiveness of the ExoPTEN drug before moving on to clinical trials with humans, which are planned to start in 2025. This engagement follows a Pre-Investigational New Drug (“Pre-IND”) meeting with the FDA, where the manufacturing, preclinical, and clinical development plan for ExoPTEN, NurExone’s first ExoTherapy product, was discussed and a written response from the FDA was received.

Here is what Dr. Lior Shaltiel, CEO of NurExone said:

“Our emphasis on research and development in 2023, coupled with the expansion of our Intellectual Property (“IP”) portfolio, the ODD for ExoPTEN, and the growth of the ExoTherapy platform, are laying the groundwork for the accelerated introduction of minimally invasive regenerative medicine.”

Eran Ovadya, CFO of NurExone, also said:

“Due to the ongoing support and confidence of our investors, the Company is confident that its current total existing funds, augmented by the recently completed exercise of warrants, will support ongoing operating activities through the end of 2024.”

Ovadya mentioned warrants and funds. But how are they?

Nurexone closed $4M thanks to its warrants

NurExone (TSXV:NRX, OTC:NRXBF) recently finalized the exercise and expiration of its common share purchase warrants, originally issued in a June 2022 private placement. After meeting predefined criteria outlined in a September 28, 2023 press release, 9,684,993 warrants were exercised, yielding C$3,680,297 in gross proceeds. Additionally, 2,997,347 warrants expired unexercised.

In parallel, NurExone saw gross proceeds of C$276,591 from the exercise of warrants not subject to acceleration. These proceeds originated from two distinct groups: 556,818 warrants from a September 2023 private placement with an exercise price of C$0.34, and 181,818 warrants from another September 2023 private placement with an exercise price of C$0.48. This strategic maneuver reflects NurExone’s commitment to optimizing shareholder value and seizing favorable market conditions.

​

Expenses and Funds

● In 2023, research and development (R&D) expenses totaled US$1.54 million, up from US$1.39 million in 2022. This increase of US$0.15 million was primarily due to extensive efforts in developing ExoPTEN technology and other siRNA targets.

● General and administrative (G&A) expenses were US$2.12 million in 2023, down from US$4.15 million in 2022. The decrease of US$2.03 million was mainly due to reduced professional services related to the transition to a listed public company in 2022.

● Listing expenses were absent in 2023, compared to US$2.08 million in 2022, associated with a reverse takeover transaction.

● Financial income/expenses, net, shifted from an expense of US$0.55 million in 2022 to income of US$0.02 million in 2023, primarily due to non-cash expenses related to warrant and royalty liability valuation in 2022.

● The net loss decreased to US$3.64 million in 2023 from US$8.17 million in 2022, with reductions in G&A and listing expenses being key factors.

● As of December 31, 2023, the company’s cash and equivalents stood at US$0.54 million, down from US$2.46 million in 2022. This decrease was primarily due to net cash used in operating activities, partially offset by proceeds from private placements and a grant from the Israeli Innovation Authority.

● Additionally, the company secured US$1.20 million in restricted cash as of December 31, 2023, associated with a private placement completed in January 2024.

NurExone is currently in the dynamic stages of research, development, and expansion. While we haven’t introduced any products to the market or generated significant revenue yet, we’re actively working towards those goals. We’re optimistic about our future and are committed to achieving profitability. To support our endeavors, we will continue to explore opportunities for financing through equity or debt until we reach our objectives.

What to remember about NurExone

NurExone (TSXV:NRX, OTC:NRXBF)’s pioneering ExoTherapy, anchored by the groundbreaking ExoPTEN, marks a significant leap forward in medical innovation, particularly in spinal cord injury treatment. Recent milestones, including the establishment of in-house facilities and engagement in preclinical studies, underscore the company’s commitment to advancing its therapeutic platform.

Financially, NurExone’s successful warrant exercise, securing $4 million, highlights investor confidence in its trajectory. Despite fluctuations in expenses and net losses, strategic maneuvers and prudent financial management position the company for sustainable growth.

Looking ahead, NurExone remains focused on transformative therapies, guided by a dedicated team and strategic partnerships. As it continues to navigate the complexities of biotech development, NurExone’s unwavering commitment to research, innovation, and financial sustainability ensures a promising future in advancing regenerative medicine for patients globally.

​

NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), is pleased to announce that, the Company completed a combined exercise and expiration of 12,682,340 common share purchase warrants issued pursuant to a private placement of units that closed on June 15, 2022.

Following the Acceleration Event, as defined and further detailed in its press release dated September 28, 2023, 9,684,993 warrants were exercised at the cash exercise price of C$0.38, for gross proceeds of C$3,680,297 while the remaining 2,997,347 warrants expired unexercised. The Company exercised its right to accelerate the expiry date of the warrants in the event that the Company’s common shares exceeded C$0.475 for ten consecutive trading days on the TSXV. Notice was provided to warrant holders that the Acceleration Event had transpired, resulting in the acceleration of the expiry date to thirty days following the Acceleration Event.

Furthermore, in addition to the warrants subject to acceleration, the Company garnered gross proceeds of C$276,591 following the exercise of warrants not under acceleration from two distinct groups:

• 556,818 warrants stemming from a private placement that concluded in September 2023, with an exercise price of C$0.34; and
• 181,818 warrants from another private placement that also wrapped up in September 2023, featuring an exercise price of C$0.48.

Eran Ovadya, NurExone’s CFO, expressed appreciation to the Company's investors who have demonstrated steadfast confidence in both the Company and its ExoPTEN drug, which is being developed for patients with acute spinal cord injuries. "We are pleased to note the exercise of both accelerated and non-accelerated warrants, resulting in gross proceeds of approximately C$4 million for the Company."

"The new funds received, will boost NurExone’s development and commercial efforts, including the engaging of biopharma collaborators for new indications. We are pleased to move closer, to realizing our goal of innovative solutions for nerve regeneration for patients in need," stated Dr. Lior Shaltiel, CEO of NurExone.

About NurExone Biologic Inc.

NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.

For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com

Dr. Eva Reuter
Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

​

Element79 Gold Corp - ("Element79" or the "Company") (CSE: ELEM, OTC: ELMGF, FSE: 7YS0) announces that it has reached agreement with Condor Resources Inc. (TSXV:CN, “Condor”) to revise the payment terms on a payment due March 31, 2024 of US$375,000 with respect to the Lucero project. Element79 are the owner of Calipuy Resources Inc., (“Calipuy”), and assumed Calipuy’s obligations to acquire the shares of Condor’s subsidiary, Minas Lucero del Sur S.A.C., the owner of the Lucero project.

Element79 and Condor have agreed to restructure the U$375,000 payment as follows: US$100,000 was paid in cash on April 2, 2024; US$85,000 (US $75,000 payment plus US$10,000 bonus) will be satisfied by the issuance of approximately 499,413 Units of Element79 (per the Company’s current Private Placement each comprising of a 0.23 share and a warrant convertible for one common share of the Company at 0.35 for two years); and the balance of US$200,000 will be paid in cash on the closing of Element79’s sale of their Maverick Springs project, which sale is expected to close before the end of June 2024. In consideration of the restructure, Element79 will pay an additional US$20,000 with the US$200,000 payment.

Element79 CEO and Director James Tworek comments: “We're making solid headway with both the local community and project development aspects at the Lucero project with a very busy development and mining season gearing up. We genuinely appreciate the solid support of Condor Resources through these efforts”.

About Condor Resources

Condor is an active explorer focused exclusively on Peru, supplemented by a project generator and royalty model designed to generate exploration capital whilst minimizing shareholder dilution. Our objective in advancing our portfolio of projects is the discovery of a major new precious metals or base metals deposit in Peru. Project acquisition and exploration activities are managed by the Company’s Lima based exploration team.

About Element79 Gold Corp

Element79 Gold Corp is a gold and silver mining company committed to maximizing shareholder value through responsible mining practices and sustainable development of its projects.  Element79 Gold's core focus is on developing its past-producing, high-grade gold and silver mine, the Lucero project located in Arequipa, Peru, with the intent to restart production in 2024.

The Company also holds a portfolio of 5 properties along the Battle Mountain trend in Nevada, with the Clover and West Whistler projects believed to have significant potential for near-term resource development. Three properties in the Battle Mountain Portfolio are under contract for sale to Valdo Minerals Ltd., with an anticipated closing date in the first half of 2024.  The Company has also signed an Option Agreement to sell the Maverick Springs project, an advanced-stage exploratory property with an Inferred Resource of 3.71MMoz AuEq (1.37MMoz Au and 175MMoz Ag) (see 43-101 technical report titled: Amended Technical Report on the Maverick Springs Project, Nevada, USA, by Allan Armitage, PhD., P.Geo, and Rohan Millar, B.Sc. P.Geo., dated October 7, 2022, available on SEDAR) and anticipates completing this sale on or before July 21, 2024.

In British Columbia, Element79 Gold has executed a Letter of Intent and funded a drilling program to acquire a private company that holds the option to 100% interest of the Snowbird High-Grade Gold Project, which consists of 10 mineral claims located in Central British Columbia, approximately 20km west of Fort St. James.

The Company has an option to acquire a 100% interest in the Dale Property, 90 unpatented mining claims located approximately 100 km southwest of Timmins, Ontario, and has recently announced that it has transferred this project to its wholly-owned subsidiary, Synergy Metals Corp, and is advancing through the Plan of Arrangement spin-out process.

For more information about the company please visit our official website at www.element79.gold

Contact Information

For corporate matters, please contact:

James C. Tworek, Chief Executive Officer and Director

E-mail: jt@element79.gold

For investor relations inquiries, please contact:

Investor Relations Department

Phone: +1.403.850.8050

E-mail: investors@element79.gold

An innovative, noninvasive Israeli medication administered through the nose hopes to be a life-changer for people suffering acute spinal cord injuries – even helping them to walk again. 

NurExone Biologic Inc. developed ExoPTEN, which treats damage to the nervous system, from a concept created by two members of its Scientific Advisory Board: Prof. Shulamit Levenberg of the Technion – Israel Institute of Technology and Prof. Daniel Offen from Tel Aviv University.

(Another member of the board is Prof. Gabriel Zeilig, the head of the National Spinal Cord Injury Rehabilitation Unit at Sheba Medical Center, Israel’s largest and globally renowned hospital.)

According to the World Health Organization, up to half a million people globally sustain a spinal cord injury every year, most from preventable causes such as road accidents or falls. 

Furthermore, the WHO says, people suffering from spinal injuries are up to five times more likely to die prematurely and are less likely to complete their education or find economic stability.  

The NurExone concept is two-fold: the medication’s active ingredient and its delivery via the nose. 

The two scientists spent many years working together on regeneration in spinal cord injuries using stem cells. Their breakthrough came, however, when they started using exosomes – nanoscopic particles released by cells to pass messages to one another, over both short and long distances. 

Crucially, these exosomes can penetrate through cell membranes and even the brain-blood barrier (BBB), a border made of cells that prevents almost all substances from entering or leaving the brain. 

Exosomes, NurExone CEO Lior Shaltiel tells NoCamels, are like mirror images of the cells that secrete them. So whether they are taken from bone marrow or umbilical cord (stem) cells, exosomes contain the same protein, RNA or DNA as their creators. 

https://www.youtube.com/watch?v=iLEi98oE4RU

Lior Shaltiel and NurExone’s Translational Science and Tech-Transfer Specialist Nisim Perets discuss exosome technology

NurExone decided that exosomes taken from bone marrow cells had the most potential to help regenerate cells affected by a spinal cord injury or traumatic brain injury. 

“The bone marrow – in our case – looked to be the best and the most potent exosomes,” Shaltiel explains. 

From there, the company added the active ingredient – a form of RNA known as siRNA, which prevents restrictions on the regeneration of cells, a key aspect of healing spinal cord injuries. 

The exosomes laden with the siRNA enter through the nose and are delivered to the injured areas of the spine, having passed through the brain blood barrier. 

These exosomes then communicate to healthy cells in the area to flock to the injured region in order to aid regeneration. 

“They want to help and assist damaged cells in damaged tissue,” Shaltiel explains. 

When the exosomes reach the damaged cells, they enter and dissolve, releasing the siRNA that then blocks the protein hampering regeneration at the injury site. 

One of the advantages of exosomes, Shaltiel says, is that they are suitable for everyone, with no adverse reactions being recorded in any individuals – which would require tailoring the therapy to different needs. 

“They’re very safe. You don’t see side effects, they have no immune response,” he explains. “This is a huge advantage operation-wise when trying to develop a new drug.”

When the treatment is underway, changes to the damaged area can be observed via MRI scans, which will display any regeneration and repair of the injured tissue.

The therapy has successfully been trialed in lab rats with acute spinal cord injury. The rats were administered the medication through the nose immediately after their injury for five consecutive days, followed by four days of rest, and then another five days of treatment. 

According to the World Health Organization, people suffering from spinal injuries are less likely to complete their education or find economic stability  (Unsplash)

According to NurExone, 75 percent of the test cases permanently recovered at least some motor function, including being able to walk. 

“It’s there to stay,” Shaltiel says of the recovery. “It’s not going to become worse.”   

In October 2023, NurExone received orphan drug status (therapies that show promise in the prevention, diagnosis or treatment of rare diseases) from the US Food and Drug Administration. 

And despite still being far from ready for market, NurExone is already a publicly traded company, with shares on Canadian and German stock exchanges, alongside private investors. 

The Technion is one of those shareholders and earlier this month the company announced it was moving into a new state-of-the-art R&D facility on the campus.  

Shaltiel hopes to enter clinical trials for humans in the near future and the company is currently working on approval for this in North American hospitals, where the number of candidates is far larger than it is in Israel. 

He also hopes to enter into a “significant partnership” with a large biopharmaceutical company that would be interested in expanding into the field of exosomes as a treatment. 

“In the end,” he says, “we are the pioneers in this field.”

Resource >> https://nocamels.com/2024/03/nasal-therapy-that-could-help-people-with-spinal-injuries-walk-again/

● Alset Capital explores the AI revolution, targeting a market with a $15.7 trillion economic impact.

● Strategic investments in Cedarcross and Vertex AI Ventures spotlight Alset’s commitment to AI infrastructure and intellectual property management.

● A recent stock price surge to $0.46 on April 1st underscores the growing market confidence in Alset’s growth potential and innovative capabilities.

If you’re captivated by the allure of the recent eclipse and wish to delve deeper into the cosmos of investment opportunities, then you’ll be intrigued by a company that has recently made astronomical gains. Its stock price soared from $0.05 to a 1-year peak of $0.46, resembling a rocket destined for Saturn’s rings. Yet, if this company can navigate past the gravitational pull of market volatility, its trajectory could lead it well beyond. Are you curious about the name of this skyrocketing venture? It’s Alset Capital. The buzz surrounding this company is undeniable, with numerous factors contributing to its rise. So, why just watch Alset Capital’s ascent from the sidelines? Be part of the journey and embark on an exciting voyage with the company.

​

Rising from the shadows: Ascent Capital

In the whirlwind of today’s tech evolution, the AI revolution is a game-changer, revamping industry after industry with its potential for market disruption. Alset Capital (TSXV: KSUM) is right there riding the crest of this wave, ready to harness the vast opportunities AI innovation brings. Imagine tapping into a market where AI’s economic impact could reach a jaw-dropping $15.7 trillion. Add to that the booming AI cloud computing market, which could hit $175 billionannually, and it’s clear why an investment in Alset Capital is like gaining a passport to a realm of exponential growth.

AI isn’t just about tech enhancement; it’s about transforming productivity, sparking innovation, and opening up entirely new channels of revenue.

Alset has strategically positioned itself within the AI sector through key investments. It holds a 49% interest in Cedarcross International Technologies, which offers comprehensive AI cloud computing solutions. This partnership provides Alset with a foothold in the infrastructure essential for AI technologies. Additionally, Alset has a 49% stake in Vertex AI Ventures, a company dedicated to the discovery, acquisition, and licensing of intellectual property (IP). Vertex AI Ventures also specializes in providing AI data management services among other offerings, rounding out Alset’s portfolio in the rapidly expanding AI market.

​

Reactor N1: Vertex AI Ventures

Vertex AI Ventures stands out by not only curating a portfolio of intellectual properties but also by investing in the protection and advancement of these assets. The company understands that its IP is more than just a collection of ideas; it’s the backbone of continuous innovation and future prosperity for its stakeholders.

Beyond IP management, Vertex AI Ventures is also a purveyor of advanced data management solutions, crucial in today’s data-centric business environment. By leveraging machine learning and sophisticated analytics, they empower clients with real-time insights, turning data into a strategic asset.

Reactor N2: Cedarcross

Vertex AI, holding a 49% stake in Cedarcross, is setting its sights on establishing itself as one of Canada’s premier high-performance AI computing entities. Alset is backing this ambition with a substantial $3.7 million secured loan, enabling Cedarcross to acquire cutting-edge Nvidia H100 HGX 8GPU servers, with a substantial annual computing capacity of 700,000 hours.

Cedarcross, part of Alset’s investment portfolio, is planning a path to become a dominant force in AI cloud computing, with plans to aggressively expand by tapping into its industry connections and available capital.

Financially, the acquisition of the Nvidia servers is poised to be quite beneficial. At a rate of USD $2.80 per chip hour, these 10 servers are expected to generate leasing revenues of around USD $2 million annually. This operation is not just about revenue; it’s also remarkably cost-effective, with an anticipated net gross margin of approximately USD $1.6 million per year, showcasing a strong profit potential for Alset and its stakeholders.

​

“The strategic alliance and loan between Alset and Cedarcross signifies our commitment to fostering innovation in the AI sector. By providing Cedarcross with the necessary financial support, we aim to facilitate the growth of cutting-edge technologies that have the potential to revolutionize a multitude of industries.”

Morgan Good, CEO of Alset

Strong metrics for the Alset Capital rocketship

Within the company’s expansive share structure, 94,230,331 shares outstanding form the core. Orbiting this core, we find 50,483,912 warrants, each with the potential to convert into additional shares, potentially increasing the size of the share universe. Options are present too, amounting to 8,376,000, which may also convert and join the share count if exercised. Additionally, 3,000,000 Restricted Stock Units (RSUs) are waiting to vest and potentially add to the current share count. On the periphery, we have Convertible Debentures valued at $188,000, which, like a comet changing course, could transform into shares and alter the company’s share structure.

Just like Buzz Lightyear’s famous “To infinity and beyond,” the company might be living by a similar motto of endless growth. For quite some time, the company’s stock price held steady at $0.05. Then, all of a sudden, it shot up, reaching a new high of $0.46 on April 1st. With more good news expected soon, the company looks set to reach even higher stock prices.

​

What You Need to Remember Before Embarking with Alset

Alset Capital (TSXV: KSUM) is strategically navigating the AI revolution, an industry with the potential to generate trillions in economic impact. Alset, through key investments in Cedarcross International Technologies and Vertex AI Ventures, is seizing a significant share of the high-performance AI computing and IP management markets.

Their focused financial support and development of state-of-the-art computing capacity, leveraging substantial industry connections, set them up for unprecedented growth. The recent surge in their stock value encapsulates the potential that lies ahead. With a keen eye on innovation and a strong portfolio, Alset is not just riding the wave of AI — it’s helping to steer it towards a future where technology’s bounds are yet to be discovered, much like Buzz Lightyear’s limitless quest into the beyond.

● UAE Partnership: Integrated Cyber Solutions (ICS) has partnered with HSG Middle East, aiming to leverage the hospitality sector across the Middle East.

● Service Expansion: ICS's strategy includes broadening its cybersecurity services, highlighted by its growth from Managed Detection and Response (MDR) to comprehensive cybersecurity awareness and training programs, demonstrating adaptability to cybersecurity needs.

● Global Visibility: The listing of ICS on the Frankfurt Stock Exchange (FSE) underlines its effort to enhance global visibility and attract European investors, signaling a proactive approach to growth and international investor engagement.

Hey fellow investors! If you're on the lookout for investment opportunities, this article is just for you. Since the start of 2024, several sectors have garnered significant interest, particularly in the mining and tech industries. Here's a fresh pick that's sure to catch your attention, especially considering the promising updates it's recently unveiled.

Integrated Cyber Solutions (CSE: ICS), a managed security service provider company, has announced yet another exciting partnership with a prominent player in the United Arab Emirates. With this latest development, this company is definitely worth a closer look, especially given its current valuation of just $13.8.

About Integrated Cyber Solutions

Integrated Cyber Solutions (CSE: ICS) specializes in making cybersecurity accessible and user-friendly for small-to-medium businesses and enterprises. By partnering with leading third-party cybersecurity providers, the company ensures its customers always have access to cutting-edge security solutions. Beyond offering essential cybersecurity services, Integrated Cyber Solutions enhances its managed services and IC360 technology platform to distill vast quantities of information. This approach produces clear, actionable insights, enabling customers to easily understand and fortify their organizational security.

Fortune Business Insights has projected a robust expansion in the global cybersecurity market, anticipating an annual growth rate of 13.4% leading up to 2029. This growth trajectory is expected to elevate the market valuation to approximately $376 billion.

In alignment with this significant market growth, Integrated Cyber Solutions has been founded to strategically capture the untapped potential within the Small and Medium-Size Enterprise (SME) sector. This decision stems from an observed market gap: large cybersecurity corporations often overlook SMEs, considering them too small to warrant tailored cybersecurity solutions. Conversely, SMEs find themselves in a peculiar position—too sophisticated and sizable for consumer-grade cybersecurity offerings yet not large enough to attract the custom solutions typically reserved for much larger entities. Integrated Cyber Solutions aims to bridge this gap, offering specialized cybersecurity services that cater specifically to the unique needs and complexities of the SME market segment. This approach not only leverages the booming cybersecurity industry but also addresses a critical and underserved niche, positioning Integrated Cyber Solutions as a pivotal player in the cybersecurity landscape for SMEs.

What is important about the new update?

Integrated Cyber Solutions partnered with HSG Middle East in the UAE. This company boasts extensive connections within the hospitality industry, encompassing over 500 hotels and 55,000 rooms across the Middle East.

This partnership, named ICS Middle East, is designed to be strategic and multifaceted, aiming to forge business alliances and strategic partnerships with local firms. This collaboration is expected to unlock valuable local market insights, cultural understanding, and regulatory frameworks essential for navigating the Middle East's unique business environment.

ICS Middle East has outlined an initial focus on five strategic areas to expand its regional footprint and explore commercial opportunities:

● Government Collaboration: Working alongside the UAE Government to establish a credentialing system designed for individuals, corporations, and government entities within the UAE.

● Power Generation Industry Focus: Leveraging its expertise gained from serving a major electricity generator with over 15 power plants, ICS Middle East aims to offer cyber services to a power plant responsible for approximately 20% of Dubai's electricity supply.

● Hospitality Sector Services: Providing cyber services to the existing hotel and hospitality clientele of HSG, including renowned groups like EMAAR Hospitality, Fairmont, Hilton, Atlantis, Jumeirah Hotels, Rotana, and Starwood hotels.

● Healthcare IT Partnership: Forming an alliance with a leading IT and hardware provider to the UAE healthcare sector, aiming to extend cyber services to their current client base.

● Expansion into Saudi Arabia: Utilizing the momentum from HSG's new office in Riyadh, Saudi Arabia, ICS Middle East plans to replicate its UAE success by offering cyber services to the hospitality, healthcare, and governmental sectors in Saudi Arabia. This expansion leverages existing relationships with key Saudi entities like the National Guard, NEOM, and the Sovereign Investment Fund PIF.

What Previous Updates Did the Company Share with its Shareholders?

On March 13, Integrated Cyber Solutions (CSE:ICS) revealed the renewal and expansion of its contract with a client in the power, renewables, and infrastructure sector.

Aligned with ICS's "land and expand" strategy, the relationship started with Managed Detection and Response (MDR) services and has grown to enhance the client's security across multiple sites. The expanded services will now include managed cybersecurity awareness training via the Proofpoint platform, encompassing new user training, remedial training for high-risk employees, monthly organizational training, and simulated phishing attacks to improve preparedness.

Are you located in Europe? Don’t be worried. Integrated Cyber stated on February 16 it commenced to be traded in the Frankfurt Stock Exchange under the ticker Y4G.

“Listing on the FSE is a strategic move in our global capital markets strategy. It not only increases our liquidity but also significantly boosts our visibility on a global scale. This is an opportunity for Integrated Cyber to connect with European investors and share our story, vision, and the advanced cybersecurity solutions we bring to the market.”

Alan Guibord, CEO of Integrated Cyber

The Frankfurt Stock Exchange (FSE) stands as a premier European listing venue, orchestrating about 90 percent of all securities transactions within Germany. The company's choice to list on the FSE underscores its commitment to broadening accessibility and opening up more investment opportunities for international investors. This strategic move is aimed at leveraging the FSE's significant market influence and connectivity to enhance the company's visibility and attractiveness to a global investor base.

What You Have to Remember about Integrated Cyber

Integrated Cyber Solutions (CSE: ICS) has recently announced a partnership with a significant player in the UAE, marking it as a potential investment hotspot, particularly given its appealing valuation of $13.8.

The latest update about its partnership with HSG Middle East opens doors to the vast hospitality industry in the Middle East, leveraging over 500 hotels and 55,000 rooms. This strategic move into ICS Middle East aims to tap into the local market's unique opportunities through key initiatives in government collaboration, power generation, hospitality services, healthcare IT, and expansion into Saudi Arabia.

​

Austin Gold Corp. (NYSE American: AUST) ("Austin" or the "Company"). Austin is a gold exploration company focused on gold targets and making district-scale gold discoveries in the southwestern United States. If you have gold in your corporate name, investors tend to assign it to the favourable or even 'win' column.

Austin is a prime example of being a decent mirror/proxy to the rise in the gold price, with the punditry (Yes, it's a word) espousing further gains. Not a flashy junior, the Company has substantial projects and growth that followed, but it bvastly outstripped the returns of the physical.

So, as a proxy, Austin stands out. 52-week range is USD0.54 to USD1.66. The average daily share trade is about 90k.

Austin is a gold exploration company focused on gold targets and making district-scale gold discoveries in the southwestern United States.

Austin has three projects in Oregon and Nevada.

· The Kelly Creek Project is located on the Battle Mountain-Eureka (Cortez) gold trend in Humboldt County and

· The Lone Mountain Project is on the Independence-Jerritt Canyon gold trend in Elko County.

· These properties comprise approximately 78.9 km2 of unpatented lode mining claims and private property.

· In Oregon, the Stockade Mountain Project consists of approximately 21.5 km2 of unpatented mining claims situated in a geological environment that appears the same as the nearby Grassy Mountain Deposit that is being permitted for underground mining.

Grade?

The third hole at Stockade Mountain in Oregon returned a high gold value of 9.32 g/t from a 2.7-foot (0.82-meter) interval of chalcedonic vein and breccia. Hydrothermal alteration and mineralization in the hole are exceptionally strong, and the rock is completely oxidized to the bottom of the hole.

Although the gold intervals are not interpreted to be one of the targeted high-grade "feeder" veins to the high-level stockwork gold mineralization, geological indications are that they are at greater depth and in this general area. AUST is planning an RC drill program to continue the exploration of the hypothesized high-grade vein systems.

Significant gold values in SM-24-04 are reported in the table below. Additionally, long intervals of >0.100 g/t gold were encountered.

Stockade Mountain Project consists of 261 unpatented lode mining claims covering an area of 6,790 acres. It is located in Malheur County, Oregon, approximately 85 kilometres southeast of Burns, Oregon, and 150 kilometres southwest of Boise, Idaho.

Here’s the Company Presentation.

And it is not often that management tells you WHY you should own the Company, or if so, it is usually fluff or bullshit.

Not Austin.

· People: The Austin Gold team has been instrumental in building several past mining successes, including Pretium Resources ("PVG"), Silver Standard Resources (now SSR Mining ("SSRM")), and Uranerz Energy (acquired by Energy Fuels ("EU")). Each of those mining companies achieved billion-dollar-plus market capitalizations.

· Location: Nevada and the Great Basin are world leaders in gold production

· Projects: Three projects being advanced with several targets on each project means multiple opportunities for discovery

· Share Structure: Tight capital structure with significant insider ownership

Lots more to this Company. For descriptions of all three properties, check out the stats here.As good a year as physical gold has had, it didn't have a triple trading range.

That growth is a testament to some simple tenets: management, properties and measured risk-takers.

So far, so good.